Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, FACS; and Banu Arun, MD, FASCO; discuss how genetic testing drives breast cancer management from screening and surgical decisions to targeted systemic therapies.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Recommend appropriate treatment strategies based on the interpretation of genetic testing results, factoring in a patient’s genetic status, personal and family history, and overall clinical presentation
• Integrate updated guideline recommendations into practice for pre- and post-genetic test counseling, and multidisciplinary care team collaboration in breast cancer treatment
• Describe the expanded role of gBRCA testing beyond familial risk in breast cancer

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme LLC.

Chair:

Patrick I. Borgen, MD

Chairman, Department of Surgery
Director, Brooklyn Breast Cancer Program
Maimonides Medical Center
Brooklyn, NY

Disclosures: Patrick I. Borgen, MD, has no relevant financial relationships with ineligible companies.

Faculty:

Don S. Dizon, MD, FACP, FASCO

Jane F. Desforges Chair in Hematology and Oncology and Professor of Medicine
Tufts University
Service Line Chiematology and Oncology
Tufts Medicine
Boston, MA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Astra Zeneca (ended), Medidata; Grant/Research Funding: BMS, Merck; Ownership interest in publicly traded companies: Doximity; Ownership Interests in Privately Held Companies: Midi

Kevin S. Hughes, MD, FACS

McKoy Rose Professor of Surgery
Medical University of South Carolina
Charleston, SC

Disclosures: Consultant: Olaparib Patent Dispute; Honoraria: AstraZeneca (Pharmaceutical Company), Hologic (Biozorb, Breast surgery devices), LabCorp(Genetic testing), Letsgetchecked (Genetic testing), TME/Aptitude Health (genetics education and consulting)

Banu Arun, MD

Associate Professor and Deputy Chairman
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Funding: CPRIT; Grant/Research Funding (paid to the institution): AstraZeneca

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on multidisciplinary breast cancer care, genetic testing, and moderate and high-risk genes, go to https://www.gotoper.com/mbcc26gbrca-activity.

Release Date

April 3, 2026

Expiration Date

April 3, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.